Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Liabilities (2021 - 2025)

Krystal Biotech's Total Liabilities history spans 5 years, with the latest figure at $114.2 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 4.36% year-over-year to $114.2 million; the TTM value through Dec 2025 reached $114.2 million, up 4.36%, while the annual FY2025 figure was $114.2 million, 4.36% up from the prior year.
  • Total Liabilities for Q4 2025 was $114.2 million at Krystal Biotech, up from $102.2 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $114.2 million in Q4 2025 and bottomed at $12.4 million in Q1 2021.
  • The 5-year median for Total Liabilities is $42.6 million (2021), against an average of $59.3 million.
  • The largest annual shift saw Total Liabilities surged 452.48% in 2022 before it plummeted 38.11% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $32.7 million in 2021, then rose by 10.7% to $36.2 million in 2022, then increased by 9.65% to $39.7 million in 2023, then surged by 175.62% to $109.5 million in 2024, then grew by 4.36% to $114.2 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Total Liabilities are $114.2 million (Q4 2025), $102.2 million (Q3 2025), and $97.7 million (Q2 2025).